Rhinomed Limited (ASX: RNO or “the Company”) a leading sleep and nasal respiratory technology company has successfully undertaken an AUD$3.6 million placement to institutional and sophisticated private investors at $0.15 per share. Read a full copy of the announcement here.
LEADING WHOLESALER PHOENIX HEALTHCARE TO WHOLESALE MUTE IN UK October 31, 2017. Melbourne, Australia. Nasal respiratory technology company Rhinomed (ASX:RNO) is pleased to announce a wholesale distribution agreement with UK based Phoenix Healthcare Distribution Limited. Under the agreement, all four SKU’s (Trial pack and three sized packs) of Mute will be available for ordering … Read more
September 14, 2017. Melbourne, Australia.Rhinomed (ASX:RNO) is pleased to announce a distribution agreement with Brojaw Inc., to begin distributing snoring and nasal breathing product Mute into the Taiwanese market. Read a full copy of the announcement here.
Leading USA Pharmacy Takes Mute Into 4300 Stores July 19, 2017. Melbourne, Australia. Respiratory technology company Rhinomed Limited (ASX:RNO) is delighted to inform investors that it has received purchase orders confirming U.S. pharmacy giant Walgreens has core ranged all 4 SKU’s (Trial pack, Small, Medium and Large) of the MUTE sleep and breathing technology … Read more
Major Expansion of Mute USA Retail Footprint Rhinomed Limited (ASX: RNO), is pleased to announce that it has been advised that its sleep and breathing technology Mute, has been added to the annual ‘large set’ planogram produced by the Hamacher Resource Group, Inc. Read a full copy of the announcement here.
Respiratory technology company Rhinomed (ASX:RNO) is pleased to announce that it has been advised by Sigma Healthcare that Mute sleep technology will form part of the 2017 core range for the Amcal and Guardian pharmacy brands. This adds to Rhinomed’s existing Sigma relationship which saw Discount Drug Stores stock Mute, meaning the majority of Sigma … Read more
GNC USA to Sell Mute Respiratory technology company Rhinomed (ASX:RNO) is pleased to announce further expansion of its North American retail distribution footprint having received confirmation that its Mute sleep technology will go on sale in 811 GNC Holdings Inc. health, wellness and performance stores. Read a full copy of the announcement here.
Rhinomed Completes Successful Capital Raise And Cornerstone Investment Australian respiratory technology company Rhinomed Limited (ASX:RNO) is pleased to advise that it has undertaken a AUD$2.1million private placement. The placement was made to two US based sophisticated investor groups under ASX Listing rule 7.1 and the company’s current 15% capacity. Read a full copy … Read more
Mute Global Distribution Milestone Update Respiratory technology company Rhinomed (ASX:RNO) is pleased to provide an update on the expansion of its global distribution program. Read a full copy of the announcement here.
FY17 Q2 Business Update + Appendix 4C Respiratory technology company Rhinomed Limited (ASX: RNO) is pleased to report a record unaudited half yearly result of $1.195 million. This follows another strong quarter of operational revenue of $662k. Download a full copy of the announcement here.
Summer 2016-2017 Newsletter March, 2017. Melbourne, Australia. Welcome to the first Investor Newsletter for 2017. We are pleased to report that Rhinomed has continued another solid 12 months of achieving our major milestones. At the end of 2015 Mute was only available in a little over 900 stores, 12 months later and Mute … Read more
THE LINDE GROUP (BOC LIMITED) TO DISTRIBUTE MUTE AND TURBINE 7th December, 2016. Melbourne, Australia. Rhinomed (ASX:RNO), the Australian respiratory technology company announced it has entered into a distribution and supply agreement with The Linde Group and its Australian subsidiary BOC Limited. BOC will manage logistics and distribute Rhinomed’s breathing technologies, Mute … Read more